National Tuberculosis Programme Viet Nam, Hanoi, Viet Nam Association for Tuberculosis and Lung Disease, Hanoi, Viet Nam.
National Tuberculosis Programme Viet Nam, Hanoi, Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France.
Int J Tuberc Lung Dis. 2018 Sep 1;22(9):983-990. doi: 10.5588/ijtld.17.0859.
Progress towards ending tuberculosis (TB) in Viet Nam includes monitoring the costs borne by patients through periodic facility-based surveys.
To document the magnitude of costs incurred by TB-affected households and establish a baseline for the top End TB indicator in Viet Nam.
A national survey with retrospective data collection and projection among 735 participants in 20 stratified clusters was conducted in 2016. Each patient was interviewed on costs, time loss, coping measures and asset ownership. Total costs were expressed as a proportion of annual household income.
In Viet Nam, 63% of households affected by TB or multidrug-resistant TB (MDR-TB) experienced costs that were >20% of their annual household income. The mean patient costs were respectively US$1054 and US$4302 per episode of TB and MDR-TB. The most significant drivers of mean costs were income loss reported and purchase of special foods, nutritional supplements, travel and accommodation.
The proportion of households experiencing catastrophic total costs due to TB in Viet Nam is high, which poses a barrier to TB diagnosis and treatment. Based on study results, programme and partners need to identify key areas for policy action and work towards a national policy guide on intervention to reduce TB patient costs.
越南在终结结核病(TB)方面取得了进展,包括通过定期的基于机构的调查监测患者的负担。
记录受结核病影响的家庭所承担费用的规模,并为越南终结结核病的首要指标建立基线。
2016 年进行了一项全国性调查,采用回顾性数据收集和 20 个分层集群中的 735 名参与者的预测。对每位患者进行了关于费用、时间损失、应对措施和资产拥有情况的访谈。总费用表示为家庭年收入的比例。
在越南,63%的结核病或耐多药结核病(MDR-TB)患者家庭的费用超过了家庭年收入的 20%。每例结核病和 MDR-TB 患者的平均费用分别为 1054 美元和 4302 美元。导致平均费用显著增加的主要因素是报告的收入损失以及特殊食品、营养补充剂、旅行和住宿的购买。
越南因结核病而导致家庭总费用灾难性增加的比例很高,这对结核病的诊断和治疗构成了障碍。根据研究结果,规划和合作伙伴需要确定政策行动的关键领域,并努力制定国家干预政策指南,以降低结核病患者的费用。